Financial Disclosure by Clinical Investigators Guide

When a sponsor submits a marketing application to the FDA, the agency does not evaluate the clinical data in isolation. It considers who conducted the studies and whether any financial relationships between those investigators and the sponsor could have influenced the results.

21 CFR Part 54 is the regulation that governs this evaluation. It requires sponsors and applicants to collect, maintain, and disclose specific financial information about clinical investigators involved in covered studies, and it gives the FDA authority to act on that information when it raises questions about data integrity.

What 21 CFR Part 54 Requires and Why It Exists

The financial disclosure regulation was established to ensure that clinical data submitted in marketing applications is reliable and free from the potential influence of financial conflicts of interest. A clinical investigator who stands to benefit financially from a favorable study outcome has an incentive, whether conscious or not, that the FDA considers relevant to how it evaluates their data.

21 CFR Part 54 is critical for maintaining the credibility of clinical trial data, which underpins regulatory decisions affecting public health. By mitigating conflicts of interest, it ensures that clinical study results are not skewed by financial incentives. Compliance with this regulation safeguards the legitimacy of research outcomes, protects patient safety, and fosters trust among healthcare providers, regulators, and the public.

The regulation applies to drug, biological product, and medical device applications. For device studies, it reaches IDE-regulated investigations. For drug and biologic studies, it applies to IND-regulated trials that generate data submitted in NDA, ANDA, BLA, and similar applications.

Who Is Subject to the Regulation

Three Parties, Three Roles

The Applicant is the party submitting the marketing application to the FDA. The applicant is responsible for submitting a complete list of all clinical investigators who conducted covered studies, and for providing either a certification of no disclosable financial interest (Form FDA 3454) or a disclosure of financial interests (Form FDA 3455) for each non-employee investigator.

The Sponsor under Part 54 has a broader definition than the IND or IDE sponsor. A sponsor under this regulation is any party that provides material support to a covered study, which can include the marketing application holder, a contract research organization, or any other entity whose financial arrangements with investigators must be disclosed. If both the parent company and its subsidiary provided material support to the study, then all investigators must report their financial arrangements with both entities.

The Clinical Investigator is any individual who is directly involved in the treatment or evaluation of research subjects in a covered study. Each clinical investigator who is not a full-time or part-time employee of the sponsor is required to provide the sponsor with sufficient accurate financial information to allow for complete disclosure or certification, and to update this information if any relevant changes occur during the study and for one year following its completion. The disclosure obligation extends to the investigator’s spouse and each dependent child.

What Is a Covered Clinical Study

Not every clinical study triggers Part 54 obligations. The regulation applies specifically to covered clinical studies.

A covered clinical study means any study of a drug or device in humans submitted in a marketing application that the applicant or FDA relies on to establish that the product is effective, or any study in which a single investigator makes a significant contribution to the demonstration of safety.

This would, in general, not include Phase I tolerance studies or pharmacokinetic studies, most clinical pharmacology studies (unless they are critical to an efficacy determination), large open safety studies conducted at multiple sites, treatment protocols, and parallel track protocols. Applicants uncertain about whether a particular study qualifies may consult with the FDA.

Key takeaway: The covered study determination drives the entire Part 54 compliance obligation. Before beginning financial disclosure collection, applicants must conduct a thorough inventory of their clinical data and identify which studies will be submitted as evidence of efficacy or safety. Those studies, and only those studies, require full Part 54 compliance.

What Must Be Disclosed

Disclosable Financial Interests Under 21 CFR 54.4(a)(3)

Compensation affected by study outcome. Any financial arrangement where the investigator’s compensation could be higher for a favorable outcome than an unfavorable one. This includes compensation explicitly tied to a favorable result, equity interests linked to study success, and royalty interests tied to product sales. This type of arrangement must always be disclosed regardless of its value.

Significant equity interest in a publicly held sponsor. An equity interest, including stock or stock options, in a publicly held sponsor company that exceeds $50,000 in value during the period of the study and for one year following its completion. The threshold applies per investigator and includes interests held by the investigator’s spouse and dependent children.

Proprietary interest in the tested product. Any proprietary interest the investigator holds in the product being studied, including a patent, trademark, copyright, or licensing arrangement.

Significant payments of other sorts. Payments by the sponsor to the investigator or the investigator’s institution that exceed $25,000 during the study period and for one year after completion. This threshold specifically excludes the costs of conducting the clinical trial itself and covers consulting fees, speaker honoraria, retainers, and similar payments that go beyond trial support.

Caution: The thresholds apply to the combined financial interests of the investigator, their spouse, and each dependent child. An investigator who personally holds $30,000 in stock of a publicly held sponsor and whose spouse holds $25,000 in the same stock has a combined equity interest of $55,000, which exceeds the disclosure threshold and requires Form FDA 3455 rather than Form FDA 3454.

What Is Not Disclosable

A number of financial arrangements are specifically excluded from Part 54 disclosure requirements. Financial compensation that is not reportable includes any support used in execution of the clinical trial, and any payments to an investigator’s institution that are not specifically targeted to the investigator personally.

Payments for the direct costs of conducting the study, including site fees, subject compensation payments, and equipment purchased at cost, are not disclosable. The regulation targets financial arrangements that go beyond standard clinical trial compensation and create a potential conflict of interest.

Forms FDA 3454 and 3455

The two submission forms under Part 54 are the primary compliance vehicle at the marketing application stage.

Form

Purpose

When Used

Who Signs

FDA 3454

Certification of no disclosable financial interest

When the investigator has no financial interests meeting the disclosure thresholds

CFO or other responsible corporate official of the applicant

FDA 3455

Disclosure statement of financial interests

When any disclosable financial interest or arrangement exists

CFO or other responsible corporate official; supported by investigator documentation

The Form FDA 3454 must be dated and signed by the chief financial officer or other responsible corporate official. If the certification covers less than all covered clinical data in the application, the applicant must include a list of the studies covered by the certification.

When a Form FDA 3455 is submitted disclosing financial interests, the applicant must also describe the steps taken to minimize the potential for bias, including any statistical adjustments or audit procedures used to assess the impact of the financial interest on the study data.

Record Retention Requirements

Financial disclosure records must be retained for two years after approval of the application. This retention requirement applies to all financial arrangement records, compensation agreements, and the documentation supporting whether Form FDA 3454 or Form FDA 3455 was submitted for each investigator.

Sponsors must obtain clinical investigator financial information before allowing the clinical investigator to participate in a covered clinical study. This means that financial disclosure collection is a pre-enrollment obligation, not something assembled at the application stage.

Critical: The FDA may refuse to file a marketing application that does not contain the financial information required by 21 CFR Part 54, or a certification that the applicant acted with due diligence to obtain it. A missing or incomplete Part 54 submission is not a minor procedural gap. It can result in the FDA refusing to file the entire marketing application.

What Happens When Disclosable Interests Are Found

A Form FDA 3455 disclosure does not automatically disqualify the investigator’s data. The FDA uses the disclosed financial information in conjunction with information about the design and purpose of the study to assess the reliability of the data.

If the FDA determines that the financial interests or arrangements raise a serious question about data integrity, the agency may initiate audits of the data derived from that investigator, request further analyses to evaluate the effect on overall study outcomes, or conduct a sensitivity analysis excluding the affected investigator’s data.

Best practice: When a disclosable financial interest exists, sponsors should proactively conduct and document a bias assessment before submission. Demonstrating that the investigator’s data is consistent with results from other study sites, that the protocol was rigidly controlled, and that statistical approaches were pre-specified significantly reduces the FDA’s concern about the financial arrangement’s potential influence on the data.

Step-by-Step Compliance Guide

Part 54 Compliance: From Study Initiation to Application Submission

Identify covered clinical studies

Before study initiation, determine whether the study will be submitted in a marketing application as evidence of efficacy or single-investigator safety. This determination drives whether Part 54 obligations apply at all.

Collect financial information before investigator enrollment

Obtain a completed financial disclosure form from each non-employee clinical investigator and subinvestigator before they begin participating in the study. The form must cover the investigator, their spouse, and each dependent child.

Maintain updated records throughout the study

Financial disclosures must be updated if any relevant changes occur during the study and for one year following its completion. Investigators should be instructed in writing to notify the sponsor immediately of any new financial arrangements or proprietary interests.

Review disclosures at study completion

Before preparing the marketing application, conduct a comprehensive review of all financial disclosure records for each covered study. Confirm that disclosures are complete for every investigator who contributed data, including sub-investigators directly involved in subject evaluation.

Prepare Forms FDA 3454 and/or 3455

For investigators with no disclosable interests, submit Form FDA 3454. For investigators with any disclosable financial interest or arrangement, submit Form FDA 3455 with complete details and the steps taken to minimize bias.

Retain records for two years post-approval

Maintain all financial disclosure records, including investigator-level disclosure forms, compensation records, and the basis for each 3454/3455 determination, for at least two years following approval of the marketing application. These records must be available for FDA review during inspections.

Common Compliance Failures

Where Sponsors Most Frequently Fall Short

Collecting disclosures too late. Many sponsors collect financial disclosure forms at the end of the study rather than before investigator enrollment. By that point, the investigator has already been involved in subject selection, treatment, and data interpretation. The regulation requires collection before participation begins.

Omitting sub-investigators. The definition of clinical investigator under Part 54 includes all individuals directly involved in the treatment or evaluation of research subjects. Sponsors that collect disclosures only from principal investigators have an incomplete Part 54 submission.

Failing to update disclosures. Financial relationships change during multi-year studies. An investigator who had no disclosable interests at enrollment may receive a consulting agreement or stock grant during the study period. Sponsors that do not actively remind investigators of their update obligations will often not learn of these changes until after the application is submitted.

Misapplying the $25,000 threshold. The significant payments threshold excludes the costs of conducting the clinical trial but applies to consulting fees, advisory board participation, speaker honoraria, and ongoing retainers. Sponsors who assume all payments made in connection with the study are excluded as trial support routinely underreport disclosable interests.

Financial Disclosure in Medical Device Studies

The Part 54 financial disclosure requirements apply to medical device studies submitted in PMA applications and, where applicable, de novo requests. For device studies conducted under an IDE, the sponsor must obtain financial disclosure information from clinical investigators before they participate in the covered study, per 21 CFR 812.43(c).

Device studies often involve a smaller number of investigational sites than drug trials, which makes the individual investigator’s data contribution proportionally larger. This increases the scrutiny the FDA applies to financial disclosures in device applications, because a single investigator with a disclosable financial interest may have contributed a material percentage of the total efficacy dataset.

“For device PMAs with few sites, the FDA pays particular attention to whether any investigator with a financial stake in the sponsor contributed disproportionately to the efficacy data. Sponsors should be prepared to show that the data is robust across all sites, not dependent on the output of any single investigator.”

Regulatory Affairs perspective, clinical-stage medical device company

Quick Reference

21 CFR Part 54 Key Numbers

$$50,000 – equity interest threshold in a publicly held sponsor (investigator + spouse + dependents)

$$25,000 – significant payments threshold (excluding clinical trial costs)

11 year – update period after study completion for investigator financial disclosures

22 years – record retention period after marketing application approval

FForm FDA 3454 – certification of no disclosable interests (signed by applicant CFO)

FForm FDA 3455 – disclosure of financial interests and bias minimization steps

Velocity Safe